Experts Debate Precedent Value of Latest Ephedra Decision
This article was originally published in The Tan Sheet
Executive Summary
Food and drug law experts tell "The Tan Sheet" they take a more reserved view than Nutraceutical Corp. attorney Jonathan Emord of a federal court decision that Emord says ensures FDA's final rule banning ephedra is not a "precedent for the creation of a supplement-wide risk-benefit adulteration standard.